Vaccine Therapy Plus Sargramostim and Interleukin-2 Compared With Nilutamide Alone in Treating Patients With Prostate Cancer
NCT00020254
Completed
RATIONALE: Vaccines made from prostate cancer cells may make the body build an immune response to kill tumor cells. Colony-stimulating factors such as sargramostim may increase the number of immune cells found in bone marrow or peripheral blood. Interleukin-2 may stimulate a person's white blood cells to kill prostate cancer cells. Androgens can stimulate the growth of prostate cancer cells. Hormone therapy using nilutamide may fight prostate cancer by reducing the production of androgens. It is... Read More
Gender:
MALE
Ages:
18 years and above
Trial Updated:
04/28/2015
Locations: Warren Grant Magnuson Clinical Center - NCI Clinical Studies Support, Bethesda, Maryland
Conditions: Prostate Cancer
Register for Updates
Immunologic Response to Inactivated Vaccine for Novel H1N1 Virus
NCT01023711
Completed
The purpose of this study is to describe the immune response to a novel H1N1 influenza vaccination in healthy adults, and to understand the factors that allow healthy adults to respond to a single dose of vaccine even if they have never previously experience novel H1N1 disease or vaccination.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/24/2015
Locations: Vaccine Research Unit Room 3-5000, Rochester, New York
Conditions: Influenza
Register for Updates
Comparing Two Pneumococcal Vaccines in Adults With Chronic Obstructive Pulmonary Disease
NCT00457977
Completed
Pneumococcal disease is a serious bacterial infection that can affect different parts of the body, including the lungs. People with chronic illnesses, such as chronic obstructive pulmonary disease (COPD), have a greater risk of developing pneumonia and meningitis as a result of pneumococcal disease. This study will compare the immune response to two types of pneumococcal vaccines in adults with COPD.
Gender:
ALL
Ages:
40 years and above
Trial Updated:
04/22/2015
Locations: University of Alabama at Birmingham, Birmingham, Alabama +17 locations
Conditions: Pulmonary Disease, Chronic Obstructive
Register for Updates
Study of Intradermal Quadrivalent Influenza Vaccine in Adults Aged 18 Through 64 Years
NCT01712984
Completed
The aim of the study is to demonstrate safety and immunogenicity of the quadrivalent influenza intradermal (QIV-ID) vaccine compared to the trivalent influenza vaccine (TIV) containing the B strain from the primary (Yamagata) lineage (TIV-ID1) and the trivalent influenza vaccine containing B strain from the alternate (Victoria) lineage (TIV-ID2) vaccines in producing protection against four strains of influenza virus. Primary Objective: * To demonstrate that QIV-ID induces an immune response (... Read More
Gender:
ALL
Ages:
Between 18 years and 64 years
Trial Updated:
04/20/2015
Locations: Not set, Hoover, Alabama +37 locations
Conditions: Influenza
Register for Updates
Immunogenicity and Safety of Group A, C, Y & W-135 Meningococcal Polysaccharide Diphtheria Toxoid Conjugate Vaccine
NCT01897402
Completed
The purpose of this study is to evaluate the production of antibodies to a new conjugate vaccine, NmVac4-A/C/Y/W-135-DT, as a measure of vaccine effectiveness, compared to the production of antibodies to a similar, licensed meningococcal (Groups A, C, Y, W-135) polysaccharide diphtheria toxoid (DT) conjugate vaccine. The investigators will also evaluate the safety of NmVac4-A/C/Y/W-135-DT™ conjugate vaccine compared to the licensed vaccine. The hypothesis is that the test vaccine is comparable t... Read More
Gender:
ALL
Ages:
Between 18 years and 55 years
Trial Updated:
04/16/2015
Locations: Mid Atlantic Urology Associates LLC, Greenbelt, Maryland +2 locations
Conditions: Meningococcal Meningitis, Meningococcal Infections
Register for Updates
Study Evaluating 13 Valent Pneumococcal Conjugate Vaccine With Trivalent Inactivated Influenza Vaccine
NCT00521586
Completed
This study is to evaluate the safety, tolerability and immune response when 13-valent pneumococcal conjugate vaccine (13vPnC) and the trivalent inactivated flu vaccine (TIV) are given together to healthy adults aged 50-59 years who are naive to 23-valent pneumococcal polysaccharide vaccine (23vPS), or when the vaccines are given 1 month apart. It will also evaluate the immune response to 13vPnC once per year for 4 years and then to a second dose of 13vPnC given 5 years after the first dose.
Gender:
ALL
Ages:
Between 50 years and 59 years
Trial Updated:
04/07/2015
Locations: Clinical Research Advantage, Inc., Chandler, Arizona +40 locations
Conditions: Influenza
Register for Updates
A Study of Fluzone® High-Dose Vaccine Compared With Fluzone® Vaccine In Elderly Adults
NCT01427309
Completed
The aim of this study is to determine the efficacy of Fluzone High-Dose compared to standard dose Fluzone for laboratory-confirmed or culture-confirmed influenza caused by influenza types/subtypes that are similar (for laboratory-confirmed) or antigenically similar (for culture-confirmed) to those contained in the respective annual vaccine formulations. Primary Objective: * To compare the clinical efficacy of Fluzone High-Dose to that of Fluzone in elderly adults, with respect to laboratory-co... Read More
Gender:
ALL
Ages:
65 years and above
Trial Updated:
03/30/2015
Locations: Not set, Mobile, Alabama +112 locations
Conditions: Influenza
Register for Updates
Evaluating the Safety and Immune Response to a Live H7N9 Influenza Virus Vaccine Followed by an Inactivated H7N9 Influenza Virus Vaccine, Given at Varying Intervals
NCT02151344
Completed
H7N9 viruses have caused a recent outbreak of severe illness in humans in China. The purpose of this study is to evaluate the safety and immune response of an H7N9 A/Anhui/13 ca influenza virus vaccine followed by an inactivated subvirion H7N9 vaccine at varying intervals.
Gender:
ALL
Ages:
Between 18 years and 49 years
Trial Updated:
03/26/2015
Locations: Johns Hopkins Bayview Medical Center, Baltimore, Maryland
Conditions: Influenza A Virus, H7N9 Subtype
Register for Updates
Safety and Immunogenicity Study of ChimeriVax West Nile Vaccine in Healthy Adults
NCT00746798
Completed
The purpose of this study is to determine if ChimeriVax West Nile vaccine is safe and effective in preventing West Nile disease in adults over 50 years of age.
Gender:
ALL
Ages:
50 years and above
Trial Updated:
03/17/2015
Locations: Advanced Clinical Research Inst., Anaheim, California +14 locations
Conditions: West Nile Fever
Register for Updates
Increasing HAART-Induced Immune Restoration With Cyclosporine
NCT00031070
Completed
The purpose of this study is to see if cyclosporine, taken when a patient begins highly active antiretroviral therapy (HAART), increases the number of CD4 T-cells (blood cells that fight infection) in a patient's blood. This study also will explore the safety of briefly giving cyclosporine to patients starting HAART.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/05/2015
Locations: University of California , Davis Medical Center, Sacramento, California +14 locations
Conditions: HIV Infections
Register for Updates
A Study to Compare the Impact of a School Based HPV Program on Vaccination Uptake and Completion Rates
NCT01526551
Completed
The purpose of this study is to evaluate the impact of a school-based Human Papillomavirus (HPV) vaccination program to determine if the combination of increased disease and vaccine education coupled with the removal of barriers will positively impact the HPV vaccination uptake and completion rates among students.
Gender:
ALL
Ages:
Between 12 years and 20 years
Trial Updated:
02/19/2015
Locations: Monticello High School, Monticello, Kentucky +1 locations
Conditions: Human Papillomavirus
Register for Updates
Booster Vaccination in Preventing Disease Recurrence in Previously Vaccinated Patients With Melanoma That Has Been Removed By Surgery
NCT01989559
Completed
This pilot clinical trial studies booster vaccination in preventing disease recurrence in previously vaccinated patients with melanoma that has been removed by surgery. Vaccines made from peptides may help the body build an effective immune response to kill tumor cells. Giving booster vaccinations may make a stronger immune response and prevent or delay the recurrence of cancer.
Gender:
ALL
Ages:
All
Trial Updated:
01/23/2015
Locations: Providence Portland Medical Center, Portland, Oregon
Conditions: Recurrent Melanoma, Stage IA Skin Melanoma, Stage IB Skin Melanoma, Stage IIA Skin Melanoma, Stage IIB Skin Melanoma, Stage IIC Skin Melanoma, Stage IIIA Skin Melanoma, Stage IIIB Skin Melanoma, Stage IIIC Skin Melanoma, Stage IV Skin Melanoma
Register for Updates